Merit Medical Systems Inc logo

Merit Medical Systems Inc(MMSI)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
SELL
SELL for 4 days
PROFIT SINCE LAST BUY
-3.7% ▼
LAST CLOSE
$86.63
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MMSI

11/13/2026: MMSI (2-star) is a SELL. SELL for 4 days. Simulated Profits (-3.70%). Updated daily EoD!

Merit Medical Systems is a global manufacturer of specialized medical devices, primarily serving the interventional cardiology, radiology, and oncology markets. The company has a leading position in niche product areas like inflation devices and benefits from a vertically integrated manufacturing model that supports consistent revenue growth. Its main growth story centers on expanding its clinical portfolio into high-growth therapeutic areas and improving operating margins. Key risks include intense pricing pressure from large, diversified medical device competitors and potential execution challenges related to its M&A-driven growth strategy. The stock may best suit growth-oriented investors looking for exposure to minimally invasive procedure trends while monitoring margin-improvement milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitMerit consistently seeks to expand its revenue base through a blend of product innovation and strategic market consolidation.
Momentum investorMixed fitMomentum suitability is conditional on the stock maintaining a positive uptrend relative to medical device sector benchmarks.
Value investorMixed fitValuation is often tied to growth expectations, making the stock's attractiveness dependent on earnings multiple expansion.
Dividend investorWeak fitThe company does not pay a cash dividend, focusing instead on reinvestment for capital growth.
Low-risk investorWeak fitAs a small-to-mid-cap medical device firm, it is subject to higher volatility than diversified large-cap healthcare stocks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highThe stock can experience significant swings based on sector-wide healthcare news and acquisition news.
Valuation riskMediumMarket pricing often assumes consistent double-digit growth, which poses a risk if expectations are missed.
Competition risk (Diversified device giants)HighLarge competitors like Abbott and Boston Scientific have greater scale to bundle products and pressure pricing.
Business qualityMediumThe company has strong niche franchises but lacks the massive scale of industry-leading diversified competitors.
Dividend incomeLow / noneMerit provides no income return for investors relying on dividend yield.
Execution riskMediumSuccess depends on the ongoing ability to integrate acquisitions and maintain R&D output effectively.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 5.19B USD
Price to earnings Ratio 32.45
1Y Target Price 107
Price to earnings Ratio 32.45
1Y Target Price 107
Volume (30-day avg) 724.2K shares
Beta 0.55
52 Weeks Range 59.74 - 94.85
Updated Date 11/14/2026
52 Weeks Range 59.74 - 94.85
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 2.67

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 23.04%
Avg. Invested days 46
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MMSI receives a 4-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
MMSI has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+6.8%) and solid cash generation (FCF margin 14.0%) are partially offset by soft profitability (net margin 8.5%), modest insider ownership of 2.44%.

Financial Health Rating

★★★★★
MMSI's financial health is supported by solid cash strength, including free-cash-flow generation (14.0% of revenue). Profitability is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is MMSI's strongest growth driver at +16.3% FY2025 versus FY2024 (solid, 4 stars). Revenue growth (+11.7%, solid) and earnings growth (+6.8%, moderate) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 108.7% and approximately 97.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.44% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 15.80%
Vanguard Portfolio Management, LLC 5.80%
Vanguard Capital Management, LLC 4.32%
State Street Corp 4.13%
Conestoga Capital Advisors, LLC 3.30%

Unit Economics (Per $1K Revenue)

★★★★★
MMSI generates approximately $487 of gross profit, $122 of operating income, and $140 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Moderate margins and solid cash conversion support a 3-star rating, while capital efficiency is soft.

Economic Dimensions

★★★★★
Effective Tax Rate: 24.83%

Quantitative Style Profile

★★★★★
MMSI has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Interventional ProductsInflation devices, catheters, and guidewires used in hospitals.Most revenue comes from the daily recurring usage of disposable tools in life-saving vascular and cardiac procedures.
Geography (International)Sales across Europe, Asia, and other regions.Global diversification provides a hedge against domestic US hospital market fluctuations.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-29
When After Market
Estimate 0.93
Actual 1.01

Profitability

Profit Margin 9.94%
Operating Margin (TTM) 13.9%

Management Effectiveness

Return on Assets (TTM) 5.04%
Return on Equity (TTM) 9.78%

Valuation

Trailing PE 32.45
Forward PE 18.55
Enterprise Value 5.51B
Price to Sales(TTM) 3.22
Enterprise Value 5.51B
Price to Sales(TTM) 3.22
Enterprise Value to Revenue 3.42
Enterprise Value to EBITDA 14.49
Shares Outstanding 59.92M
Shares Floating 58.51M
Shares Outstanding 59.92M
Shares Floating 58.51M
Percent Insiders 2.44
Percent Institutions 108.72

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.